279 related articles for article (PubMed ID: 22892341)
1. Dissociable effects of the cannabinoid receptor agonists Δ9-tetrahydrocannabinol and CP55940 on pain-stimulated versus pain-depressed behavior in rats.
Kwilasz AJ; Negus SS
J Pharmacol Exp Ther; 2012 Nov; 343(2):389-400. PubMed ID: 22892341
[TBL] [Abstract][Full Text] [Related]
2. Effects of μ-opioid receptor agonists in assays of acute pain-stimulated and pain-depressed behavior in male rats: role of μ-agonist efficacy and noxious stimulus intensity.
Altarifi AA; Rice KC; Negus SS
J Pharmacol Exp Ther; 2015 Feb; 352(2):208-17. PubMed ID: 25406170
[TBL] [Abstract][Full Text] [Related]
3. Relief of Pain-Depressed Behavior in Rats by Activation of D1-Like Dopamine Receptors.
Lazenka MF; Freitas KC; Henck S; Negus SS
J Pharmacol Exp Ther; 2017 Jul; 362(1):14-23. PubMed ID: 28411257
[TBL] [Abstract][Full Text] [Related]
4. Effects of nicotinic acetylcholine receptor agonists in assays of acute pain-stimulated and pain-depressed behaviors in rats.
Freitas KC; Carroll FI; Negus SS
J Pharmacol Exp Ther; 2015 Nov; 355(2):341-50. PubMed ID: 26359313
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological modulation of neuropathic pain-related depression of behavior: effects of morphine, ketoprofen, bupropion and [INCREMENT]9-tetrahydrocannabinol on formalin-induced depression of intracranial self-stimulation in rats.
Leitl MD; Negus SS
Behav Pharmacol; 2016 Jun; 27(4):364-76. PubMed ID: 26588213
[TBL] [Abstract][Full Text] [Related]
6. Effects of kappa opioids in an assay of pain-depressed intracranial self-stimulation in rats.
Negus SS; Morrissey EM; Rosenberg M; Cheng K; Rice KC
Psychopharmacology (Berl); 2010 Jun; 210(2):149-59. PubMed ID: 20101391
[TBL] [Abstract][Full Text] [Related]
7. Effects of the δ opioid receptor agonist SNC80 on pain-related depression of intracranial self-stimulation (ICSS) in rats.
Negus SS; Rosenberg MB; Altarifi AA; O'Connell RH; Folk JE; Rice KC
J Pain; 2012 Apr; 13(4):317-27. PubMed ID: 22424913
[TBL] [Abstract][Full Text] [Related]
8. Effects of pain- and analgesia-related manipulations on intracranial self-stimulation in rats: further studies on pain-depressed behavior.
Pereira Do Carmo G; Stevenson GW; Carlezon WA; Negus SS
Pain; 2009 Jul; 144(1-2):170-7. PubMed ID: 19435650
[TBL] [Abstract][Full Text] [Related]
9. Differential tolerance to morphine antinociception in assays of pain-stimulated vs. pain-depressed behavior in rats.
Altarifi AA; Negus SS
Eur J Pharmacol; 2015 Feb; 748():76-82. PubMed ID: 25530266
[TBL] [Abstract][Full Text] [Related]
10. Effects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats.
Kwilasz AJ; Abdullah RA; Poklis JL; Lichtman AH; Negus SS
Behav Pharmacol; 2014 Apr; 25(2):119-29. PubMed ID: 24583930
[TBL] [Abstract][Full Text] [Related]
11. Effects of peripherally restricted κ opioid receptor agonists on pain-related stimulation and depression of behavior in rats.
Negus SS; O'Connell R; Morrissey E; Cheng K; Rice KC
J Pharmacol Exp Ther; 2012 Mar; 340(3):501-9. PubMed ID: 22128346
[TBL] [Abstract][Full Text] [Related]
12. Effects of the noncompetitive N-methyl-d-aspartate receptor antagonists ketamine and MK-801 on pain-stimulated and pain-depressed behaviour in rats.
Hillhouse TM; Negus SS
Eur J Pain; 2016 Sep; 20(8):1229-40. PubMed ID: 26914635
[TBL] [Abstract][Full Text] [Related]
13. Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed-dose ratio.
Maguire DR; France CP
Eur J Pharmacol; 2018 Jan; 819():217-224. PubMed ID: 29183835
[TBL] [Abstract][Full Text] [Related]
14. Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.
Lazenka ML; Moerke MJ; Townsend EA; Freeman KB; Carroll FI; Negus SS
Psychopharmacology (Berl); 2018 Jan; 235(1):203-213. PubMed ID: 29063139
[TBL] [Abstract][Full Text] [Related]
15. Behavioral Characterization of κ Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats.
Minervini V; Dahal S; France CP
J Pharmacol Exp Ther; 2017 Feb; 360(2):280-287. PubMed ID: 27903642
[TBL] [Abstract][Full Text] [Related]
16. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
17. Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity.
Katsidoni V; Kastellakis A; Panagis G
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2273-84. PubMed ID: 23830148
[TBL] [Abstract][Full Text] [Related]
18. Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl.
Maguire DR; France CP
Eur J Pharmacol; 2016 Aug; 784():199-206. PubMed ID: 27184925
[TBL] [Abstract][Full Text] [Related]
19. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
20. Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.
Wiebelhaus JM; Grim TW; Owens RA; Lazenka MF; Sim-Selley LJ; Abdullah RA; Niphakis MJ; Vann RE; Cravatt BF; Wiley JL; Negus SS; Lichtman AH
J Pharmacol Exp Ther; 2015 Feb; 352(2):195-207. PubMed ID: 25398241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
